Product Wiki · Recalls · EU Safety Gate (RAPEX)

Sko "Drift Cat JR" — recall 0327/11

EU Safety Gate (RAPEX) · Denmark · 2011-04-08 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
0327/11
Date of alert
2011-04-08
Country / jurisdiction
Denmark
Risk level
Serious risk
Risk type
Chemical
Brand
PUMA
Product category
Clothing, textiles and fashion items
Product type
Shoes "Drift Cat JR"
Reported risk: Produktet udgør en kemisk risiko, fordi det indeholder mere end 0,1 mg/kg dimethylfumarat (DMF).Dimethylfumarat er et stof, som er stærkt sensibiliserende ved kontakt med huden, og forbrugerprodukter, der indeholder dimethylfumarat, er forbudt i henhold til Kommissionens beslutning 2009/251/EF.
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Shoes "Drift Cat JR"

Risk Description (original English): The product poses a chemical risk because it contains more than 0.1 mg/kg of dimethylfumarate (DMF).Dimethylfumarate is a substance which is strongly sensitising on contact with the skin, and consumer products containing dimethylfumarate are banned according to Commission Decision 2009/251/EC.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/1954

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.